Bone is a dynamic tissue that is regulated by the activity of bone-resorbing osteoclasts and boneforming osteoblasts. Excessive osteoclast formation causes diseases such as osteoporosis and rheumatoid arthritis. Natural substances may be useful as therapeutic drugs to prevent many diseases in humans because they avoid the many side effects of treatment with chemical compounds. 
Introduction
The balance between bone-resorbing osteoclasts and bone-forming osteoblasts is important to bone homeostasis. Many factors tightly regulate bone resorption and bone formation in vivo to maintain bone homeostasis (Suda et al., 1999; Boyle et al., 2003) . Bone erosion through excessive osteoclast formation is associated with alterations including estrogen deficiency and increases in inflammatory cytokines (Abu-Amer et al., 1997; Miyaura et al., 2003) and in turn causes bone diseases such as rheumatoid arthritis, periodontal disease, osteoporosis, and periprosthetic osteolysis. In addition, under certain conditions such as aging or prolonged smoking, bone loss is caused by a defect in the boneforming osteoblasts (Merkel et al., 1999; Liu et al., 2001; Redlich et al., 2002) . Most therapeutic drugs currently used to treat bone disease inhibit osteoclast formation or bone resorption. Consequently, there is a need for effective therapeutic drugs that improve the quality and quantity of bone.
Osteoclasts, which are the cells primarily responsible for bone resorption, are of hamatopoietic origin. Osteoclast differentiation is regulated by multiple processes through differential gene expression, one of which is characterized by the fusion of osteoclast precursors. Osteotropic agents including, IL-1, IL-6, IL-11, IL-15, IL-17, TNF-, PGE2 and PTH cause bone loss by increasing osteoclast formation (Suda et al., 1999; Hofbauer et al., 2000) . Receptor activator of NF-B ligand (RANKL), which is an essential osteoclastogenic cytokine, recruits TNF receptor-associated factor (TRAF) proteins through binding to its receptor, RANK, on the surface of osteoclast precursors. TRAFs activate various signaling pathways, including c-Src, PI3-kinase/Akt, and MAPK (Anderson et al., 1997; Lee and Kim, 2003) . Several transcription factors, including NF-B, c-Fos, NFATc1, PU1 and MITF, are activated by RANKL and are important for osteoclast differentiation (Teitelbaum et al., 2003) . In particular, expression of c-Fos induced by RANKL plays an Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1 essential role in the initiation of osteoclast differentiation. c-Fos causes the expression of NFATc1 during RANKL-mediated osteoclast differentiation (Matsuo et al., 2004) . NFATc1 can induce osteoclast differentiation in the absence of RANKL. Thus, NFATc1 is an essential factor in osteoclast differentiation (Takayanagi et al., 2002) .
Tanshinones are the major component of Danshen, the dried roots of Salvia miltiorrhiza Bunge (Labiatae) that is used as a drug in traditional Chinese medicine (Hazra et al., 2004; Hur et al., 2005) . Tanshinones have been widely used to treat menorrhalgia, insomnia, coronary disease, and cardiovascular disease (Takahashi et al., 2002; Han et al., 2005) . Furthermore, tanshinone IIA has been shown to be a potent antioxidant and to have anticancer activity against various cancer cells (Wu et al., 1998; Wang et al., 2005) . Although tanshinone IIA has been used as a medicinal agent in the treatment of many diseases, its role in osteoclast-related bone disease remains unknown.
We showed previously that tanshinone IIA greatly inhibits osteoclast differentiation and suppresses bone resorption through disruption of the actin ring . Here we examine the precise inhibitory mechanism of tanshinone IIA on RANKLinduced osteoclast differentiation. This study shows that tanshinone IIA prevents osteoclast differentiation by inhibiting c-Fos and NFATc1 expression.
Materials and Methods

Reagents
Tanshinone IIA was isolated from Danshen as described previously . Recombinant human RANKL and macrophage CSF (M-CSF) were purchased from PeproTech EC (London, England). Antibody to c-Fos was obtained from Cell Signaling Technology (Beverly, MA). Antibodies to NFATc1 and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). pMX-IRES-EGFP, pMXc-Fos-IRES-EGFP, and pMX-NFATc1-IRES-EGFP vectors were kindly provided by Dr. Nacksung Kim (University of Chonnam).
Isolation of osteoclast precursors and osteoclastogenesis
Osteoclast precursors were prepared as previously described with some modification (Park et al., 2005) . Briefly, bone marrow cells were obtained from the tibia and femur of 5-week-old male ICR mice. Bone marrow cells were suspended in -MEM (Welgene) containing 10% FBS (Gibco BRL) and antibiotics (Sigma) and were cultured for 1 day in the presence of M-CSF (10 ng/ml). After 1 day, nonadherent cells were seeded on a 10-cm bacterial culture dishes and cultured for 3 days in the presence of M-CSF (30 ng/ml) and further adherent cells were used as osteoclast precursors. For the osteoclast differentiation assay, osteoclast precursors were cultured for 4 days with M-CSF (30 ng/ml) and RANKL (50 ng/ml) in the presence or absence of tanshinone IIA (10 g/ ml). Alternatively, calvarial osteoblasts were isolated from 1-day-old ICR mouse as described previously . Briefly, mouse calvariae were obtained from pericranium and washed with HBSS containing antibiotics. Calvariae were digested 5 times for 15 min in 0.1% collagenase and 0.2% dispase. Cells were cultured for 3 days and adherent cells were used as osteoblasts. Osteoblasts and bone marrow cells were cocultured for 6 days with TNF-(20 ng/ml), IL-1 (10 ng/ml), or LPS (1 µg/ml) in the presence or absence of tanshinone IIA (10 µg/ml).
Reverse transcription (RT)-PCR analysis
For RT-PCR assays, total RNA was isolated by using the TRI reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Two micrograms of total RNA from each sample was reverse transcribed in a mixture containing oligo dT primer, dNTP, reverse transcriptase buffer, RNase out, DTT, and Superscript II reverse transcriptase (Invitrogen). cDNA (1 l) was amplified by PCR to generate the genes listed as follows: RANK sense, 
Immunoblotting
Cells were lysed in lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM NaF, 1 mM Na3VO4, and 1% deoxycholate) containing protease inhibitors. Cell lysates were centrifuged at 16,000 × g for 20 min, and total protein was measured with a DC Protein Assay kit (Bio-Rad, Hercules, CA). Equal amounts of protein were electro-phoresed by 10-15% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Amersham Biosciences, Piscataway, NJ). Protein levels were analyzed by immunoblotting with antibodies to c-Fos, NFATc1, and actin that were detected by using enhanced chemiluminescent reagents.
Retrovirus preparation
For retrovirus preparation, Plat E packaging cells were transiently transfected with pMX-IRES-EGFP, pMX-c-Fos-IRES-EGFP, or pMX-NFATc1-IRES-EGFP vectors by using Lipofectamine 2000 as recommended by the manufacturer. Six to eight hour after transfection, the medium was replaced with DMEM containing 10% FBS and antibiotics. Culture supernatant fluid containing retrovirus was collected 48 h after transfection and was used as a retrovirus.
Luciferase assay
NFATc1 luciferase reporter gene was kindly provided by Dr. Nacksung Kim (University of Chonnam). HEK 293T cells were plated in 24-well plates and transiently transfected with RANK and the AP-1 or NFATc1 leuciferase reporter genes using Lipofectamine 2000 and incubated for 24 h with or without tanshinone IIA. The cells were lysed with lysis buffer, and the luciferase activities were measured using a luciferase reporter assay system (Promega, Madison, WI). 
Statistical analysis
All quantitative results are presented as means ± S.D. Statistical significance was analyzed by using Student's t test. P values ＜ 0.05 were considered to be statistically significant and are defined with an asterisk.
Results
Tanshinone IIA inhibits RANKL-mediated osteoclast differentiation
Tanshinone IIA greatly suppressed RANKL-mediated osteoclast differentiation in osteoclast precursors ( Figure 1A and B) . We also examined the alteration of expression of RANK and c-Fms, which act as receptors for RANKL and M-CSF, respectively. Osteoclast precursors were treated with DMSO or tanshinone IIA for various times in the presence of M-CSF. M-CSF increased RANK mRNA expression in osteoclast precursors, as previously reported (Miyamoto et al., 2000) . Tanshinone IIA did not change the expression of RANK and c-Fms in osteoclast precursors ( Figure 1C ). These results suggest that tanshinone IIA does not inhibit signaling pathways, which involved in M-CSF-induced RANK expression and that tanshinone IIA may affect RANKL-induced signaling involved in osteoclastogenesis.
Tanshinone IIA suppresses c-Fos and NFATc1 expression induced by RANKL Osteoclast differentiation is regulated through the induction of various genes in response to RANKL. In particular, c-Fos and NFATc1 are well known to play an essential role in the differentiation of osteoclast precursors (Takayanagi et al., 2002; Hirotani et al., 2004) . We thus studied whether tanshinone IIA regulates the expression of c-Fos and NFATc1 in response to RANKL. Osteoclast precursors were pretreated with DMSO or tanshinone IIA (10 g/ml) and further stimulated with RANKL (100 ng/ml) for various times in the presence of M-CSF. Densito- Overexpression of c-Fos reverses the inhibitory effect of tanshinone IIA on osteoclast differentiation. pMX-IRES-EGFP or pMXc-Fos-IRES-EGFP vectors were transiently transfected into Plat E cells. After 6-8 h, the medium was changed and the culture supernatant fluid was used as a retrovirus as described in Materials and methods. (A) Osteoclast precursors were infected with control or c-Fos retrovirus for 7 h in the presence of M-CSF (30 ng/ml) and polybrene (6 g/ml). The medium was replaced and further treated with or without tanshinone IIA (10 g/ml) for 48 h. Cell lysates were immunoblotted with antibodies to c-Fos and NFATc1. (B) HEK 293T cells were seeded in a 24-well plates and transiently transfected with AP-1 reporter gene or RANK and AP-1 reporter gene. Cells were incubated for 24 h in the presence or absence of tanshinone IIA. 24 h after transfection, the cells were lysed and assayed for luciferase activity using a luciferase reporter assay system. (C) HEK 293T cells were transiently transfected with NFATc1 reporter gene or RANK and NFATc1 reporter gene. Luciferase assay was performed as above. (D) Osteoclast precursors were infected with control or c-Fos retrovirus as in (A) and were then cultured for 5 days with M-CSF (30 ng/ml) and RANKL (100 ng/ml) in the presence or absence of tanshinone IIA (10 g/ml). Cells were fixed and stained for TRAP. (E) TRAP + cells were counted as osteoclasts.
metric value of RT-PCR normalized by GAPDH intensity showed that tanshinone IIA greatly inhibited the expression of NFATc1 mRNA and slightly suppressed c-Fos mRNA expression in response to RANKL (Figure 2A) . Consistent with the results of the RT-PCR analyses, protein levels of c-Fos and NFATc1 were increased in response to RANKL, but the expression of both c-Fos and NFATc1 was significantly inhibited by tanshinone IIA ( Figure 2B) . Thus, tanshinone IIA may inhibit osteoclast differentiation by inhibiting c-Fos and NFATc1 expression in response to RANKL.
Inhibition of osteoclast differentiation by tanshinone IIA is reversed by overexpression of c-Fos
To elucidate the mechanism by which tanshinone IIA inhibits c-Fos and NFATc1 expression, we infected osteoclast precursors with control retrovirus or c-Fos retrovirus for 7 h in the presence of M-CSF (30 ng/ml) and polybrene (6 g/ml). The medium was replaced with fresh -MEM containing 10% FBS and antibiotics and further cultured for 48 h with M-CSF in the presence or absence of tanshinone IIA. As shown in Figure 3A , the expression of c-Fos and NFATc1 induced by c-Fos retroviral infection com - (A) Osteoclast precursors were infected with control retrovirus or NFATc1 retrovirus for 7 h in the presence of M-CSF (30 ng/ml) and polybrene (6 g/ml). Infected cells were visualized by confocal microscopy. (B) Osteoclast precursors were infected with control or NFATc1 retrovirus as in (A) and then cultured for 5 days with M-CSF (30 ng/ml) and RANKL (100 ng/ml) in the presence or absence of tanshinone IIA (10 g/ml). Cells were fixed and stained for TRAP. (C) TRAP + cells were counted as osteoclasts.
pletely rescued the inhibitory effect of tanshinone IIA. Furthermore, we examined for direct evidence that tanshinone IIA inhibits the c-Fos and NFATc1 transcriptional activity by cotransfecting HEK 293T cells with RANK and the AP-1 or NFATc1 promoterluciferase gene. RANK-mediated AP-1 promoter activity was inhibited in the presence of tanshinone IIA. However, tanshinone IIA does not inhibit NFATc1 transcriptional activity ( Figure 3B and C) . These results suggest that tanshinone IIA specifically regulates c-Fos expression in response to RANKL rather than regulating NFATc1 expression. Next we investigated whether overexpression of c-Fos in osteoclast precursors could rescue the inhibition of osteoclast differentiation by tanshinone IIA. After infection with control or c-Fos retrovirus, cells were cultured for 5 days with M-CSF and RANKL in the presence or absence of tanshinone IIA. Osteoclast differentiation was significantly higher after infection of osteoclast precursors with c-Fos retrovirus than after infection with control retrovirus in the presence of tanshinone IIA ( Figure 3D and E). These results suggest that tanshinone IIA suppresses osteoclast differentiation through inhibition of c-Fos expression.
NFATc1 rescues osteoclast differentiation in the presence of tanshinone IIA
The induction of NFATc1 in osteoclast precursors is essential for osteoclast differentiation and is regulated by both c-Fos and the calcium/calcineurin pathways (Takayanagi et al., 2002) . Inhibition of NFATc1 by tanshinone IIA is associated with inhibition of c-Fos in response to RANKL. Therefore, we examined whether NFATc1 could overcome the inhibition of osteoclast differentiation caused by tanshinone IIA. After infection of osteoclast precursors with control and NFATc1 retrovirus, the medium was replaced with fresh -MEM containing 10% FBS and antibiotics and further cultured for 48 h with M-CSF. GFP-expressed cells were visualized by confocal microscopy, and the infection efficiency of the control and NFATc1 retroviruses was more than 90% ( Figure 4A ). Osteoclast precursors were infected with control or NFATc1 retrovirus in the presence of M-CSF (30 ng/ml) and polybrene (6 g/ml) and further cultured for 5 days with M-CSF (30 ng/ml) and RANKL (50 ng/ml) in the presence or absence of tanshinone IIA (10 g/ml). As shown in Figure 4B and C, overexpression of NFATc1 rescued the blockage of osteoclast differentiation in the presence of tanshinone IIA. Thus, the inhibitory effects of tanshinone IIA on osteoclast differentiation result from the decrease in NFATc1 by inhibition of c-Fos.
Discussion
Bone is a dynamic tissue that is maintained by the balance between bone formation and bone resorption; this balance can be easily upset by chronic inflammation, menopause, and aging (Karsenty et al., 2002) . Bone erosion results from excessive osteoclast formation rather than damage to osteoblast activity. Therefore, the development of drugs that act to regulate osteoclast formation is important to prevent bone disease. Previously, we reported that tanshinone IIA significantly inhibits the differentiation of osteoclast precursors mediated by RANKL . Two key factors, RANKL and M-CSF, regulate the expression of various genes in osteoclast precursors by binding to their receptors, RANK and c-Fms, respectively, the levels of which are important in osteoclast differentiation. In particular, expression of c-Fms is a crucial feature of osteoclast progenitors. The addition of M-CSF to osteoclast progenitors causes the expression of RANK; thereby, RANKL induces differentiation into osteoclasts (Miyamoto et al., 2000) . Although tanshinone IIA inhibits osteoclast differentiation, it does not alter the expression of RANK or c-Fms (Figure 1 ). These results suggest that tanshinone IIA suppresses osteoclast differentiation induced by RANKL.
A member of the TNF superfamily, RANKL mediates multiple signaling pathways via RANK in osteoclast precursors and activates critical transcription factors for osteoclast differentiation and function (Suda et al., 1999; Boyle et al., 2003; Lee and Kim, 2003) . One such transcription factor is NFATc1, which is expressed in osteoclast precursors through Ca 2+ oscillation and c-Fos in response to RANKL and that is required for the regulated expression of many genes, including TRAP, calcitonin receptor, and cathepsin K (Takayanagi et al., 2005) . Thus, regulation of NFATc1 expression in osteoclast precursors has significant consequences for bone disorder therapeutics. We found that the inhibition of osteoclast differentiation by tanshinone IIA coincides with regulation of c-Fos and NFATc1. Tanshinone IIA slightly inhibits the mRNA expression of endogenous c-Fos induced by RANKL but completely inhibits the expression of the c-Fos protein ( Figure  2) . Therefore, we hypothesized that down-regulation of c-Fos protein is involved in c-Fos mRNA degradation. However, tanshinone IIA did not affect the expression of exogenous c-Fos induced by c-Fos retroviral infection (Figure 3) or the stability of c-Fos mRNA (data not shown). These results indicate that tanshinone IIA does not affect the mRNA or protein stability of c-Fos or its posttranscriptional regulation. Our previous results indicate that tanshinone IIA causes alteration of RANKL-induced signaling pathways including ERK , a known signaling pathway to regulate c-Fos expression (Whitmarsh et al., 1995) . Thus, this altered signaling pathway is related to inhibitory effect of tanshinone IIA on RANKL-induced c-Fos expression.
c-Fos, however, plays an important role in the expression of NFATc1, which is an essential factor for osteoclast differentiation. We also found that overexpression of c-Fos caused by c-Fos retroviral infection can rescue NFATc1 expression in the presence of tanshinone IIA (Figure 3) . However, the inhibitory effect of tanshinone IIA on RANKL-mediated osteoclast differentiation was not entirely rescued by c-Fos or NFATc1 administration. Actually, NFATc1 is essential for osteoclast differentiation but is not sufficient for osteoclast differentiation in the absence of RANKL. Other transcription factors, including NF-B, MITF, activator protein 1, and PU1, are required for osteoclast differentiation (Teitelbaum et al., 2003; Walsh et al., 2003) . These results indicate that osteoclast differentiation induced by RANKL requires several transcription factors for cooperating with NFATc1. We showed previously that tanshinone IIA suppresses Akt, ERK, and NF-B activation in response to RANKL . Thus, we conclude that tanshinone IIA prevents functional cooperation between NFATc1 and NF-B in response to RANKL.
In summary, we investigated the effect of tanshinone IIA on osteoclast formation. Tanshinone IIA greatly inhibits osteoclast formation by inhibiting the expression of c-Fos and NFATc1 induced by RANKL. Taken together, our results suggest that tanshinone IIA probably plays an important role in inhibiting bone loss by preventing osteoclast formation.
